Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock

• Published in: Shock (Augusta, Ga.) Vol. 3; no. 4; p. 235
• Main Authors: Pruitt, J H, Copeland, 3rd, E M, Moldawer, L L
• Format: Journal Article
• Language: English
• Published: United States 01.04.1995
• Subjects: Humans; Interleukin-1 - antagonists & inhibitors; Interleukin-1 - metabolism; Sepsis - metabolism; Shock, Septic - metabolism; Systemic Inflammatory Response Syndrome - metabolism
• ISSN: 1073-2322
• DOI: 10.1097/00024382-199504000-00001

Interleukin-1 (IL-1) is one of several proinflammatory cytokines produced during infection, sepsis, and the systemic inflammatory response syndrome (SIRS) that serves to initiate the host inflammatory response and to integrate nonspecific immunity. Many of IL-1's biologic effects are beneficial to the host in times of stress, but when produced for extended periods of time or in excessive quantities, IL-1 contributes to morbidity and mortality. In fact, excessive IL-1 production has been directly linked to the development of hypotension, shock, multi-organ system failure, hematologic dyscrasia, and death in patients and animals with sepsis, SIRS, and septic shock. Recent research interest has focused on IL-1 inhibition to improve outcome in sepsis and septic shock. This article will review the role for IL-1 in sepsis and septic shock, and the function and status of the IL-1 receptors and IL-1 receptor antagonist in modulating IL-1 actions. The results of investigations of IL-1 inhibition in animal models and in human subjects with sepsis and septic shock will also be reviewed.